CV vs NEOG vs LNTH Stock Comparison

CapsoVision, Neogen and Lantheus Holdings Prices as of Nov 16, 2026 Peers: Industry group
CV CapsoVision, Inc
$6.47 -0.9% 1M +26.4% 1Y
Market cap
$334.51M
P/E
–
Revenue (TTM)
$13.92M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
NEOG Neogen Corp
$10.88 -7.9% 1M +70.3% 1Y
Market cap
$2.38B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
LNTH Lantheus Holdings, Inc.
$101.72 +2.0% 1M +91.9% 1Y
Market cap
$6.65B
P/E
24.6x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
9 wins

Head to Head

10 decided of 12

Lantheus Holdings leads on 9 of the 12 questions below (Lantheus Holdings 9, CapsoVision 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCVNEOGLNTHLeader
Larger companyMarket capitalisation $334.51M $2.38B $6.65B LNTH
Cheaper on earningsLower P/E, profitable companies only -11.4x -42.5x 24.6x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 35.1x 17.4x LNTH
Faster revenue growthRevenue growth, trailing twelve months +6.4% -0.3% +2.4% CV
More profitableNet margin, trailing twelve months -210.1% -6.3% 17.3% LNTH
Better return on capitalReturn on invested capital — -0.2% 12.0% LNTH
Less leveragedLower net debt / EBITDA — 5.4x -0.3x LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +26.4% +70.3% +91.9% LNTH
Better 5-year returnAnnualised price return, 5 years — -24.3%/yr +28.3%/yr LNTH
Less volatileAnnualised volatility, 1 year 95.6% 55.8% 30.1% LNTH
Higher overall scoreMean of the five percentile scores vs peers 30/100 59/100 80/100 LNTH

Percentile Scorecard

CVNEOGLNTH

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCVNEOGLNTH
Valuation 12 #213 of 243 72 #68 of 243 80 #49 of 243
Growth 6 #214 of 228 48 #119 of 228 70 #69 of 228
Profitability 20 #179 of 222 63 #82 of 222 96 #11 of 222
Financial Health 90 #27 of 248 48 #129 of 248 69 #77 of 248
Shareholder Returns 23 #122 of 159 61 #63 of 159 85 #24 of 159
Overall 30 59 80
  • CV ranked among 252 companies in Medical Devices and Diagnostics
  • NEOG ranked among 252 companies in Medical Devices and Diagnostics
  • LNTH ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCVNEOGLNTHSPY
1 month -0.9%-7.9%+2.0% -3.0%
3 months +0.3%-8.3%+0.8% -4.2%
6 months +1.7%+27.1%+9.2% +0.2%
Year to date -39.5%+55.7%+52.8% +8.5%
1 year +26.4%+70.3%+91.9% +10.1%
3 years —-32.6%+49.1% +64.1%
3 years, per year —-12.3%+14.3% +18.0%
5 years —-75.1%+247.3% +58.1%
5 years, per year —-24.3%+28.3% +9.6%
10 years —-52.0%+1,024.0% +239.6%
10 years, per year —-7.1%+27.4% +13.0%

Risk

MeasureCVNEOGLNTHSPY
Volatility, 1Y 95.6%55.8%30.1% 13.8%
Downside volatility, 1Y 88.8%47.8%24.7% 14.2%
Beta vs S&P 500, 1Y 0.711.430.45 1.00
Return / volatility, 1Y 0.281.263.05 0.74
Max drawdown, 5Y -67.8%-90.6%-59.5% -25.4%
From 52-week high -55.1%-22.2%-8.3% -5.0%
52-week high $14.42$13.98$110.94 $779.14
52-week low $4.64$5.41$52.50 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCVNEOGLNTH
P/E now vs peer median -10.4xmedian 26.5x -43.7xmedian 26.5x 24.6xmedian 26.5x
P/S now vs peer median 23.2xmedian 2.7x 2.8xmedian 2.7x 4.3xmedian 2.7x
EV/EBITDA now vs peer median -10.3xmedian 18.6x 27.5xmedian 18.6x 16.9xmedian 18.6x
P/FCF now vs peer median -11.0xmedian 25.6x 49.2xmedian 25.6x 16.9xmedian 25.6x
P/B now vs peer median 12.3xmedian 2.5x 1.2xmedian 2.5x 4.9xmedian 2.5x
PEG now vs peer median —median 0.98 1.22median 0.98 0.64median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCVNEOGLNTH
Revenue $13.92M $883.99M $1.56B
Gross profit $6.92M $418.98M $957.06M
Operating income -$29.52M -$7.38M $290.93M
Net income -$29.25M -$56.10M $269.91M
Free cash flow -$29.28M $49.80M $393.09M
R&D $20.27M $19.76M $217.83M
EPS (diluted) $-0.58 $-0.26 $3.95
Cash & equivalents $21.76M $172.00M $683.61M
Total debt – $774.20M $571.74M
Shares (diluted) 50.57M 218.10M 68.41M
Enterprise value $275.63M $1.72B $4.51B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCVNEOGLNTH
P/E -10.4x -43.7x 24.6x
P/FCF -11.0x 49.2x 16.9x
P/Operating cash flow -11.1x 28.7x 16.2x
P/S 23.2x 2.8x 4.3x
P/B 12.3x 1.2x 4.9x
P/Tangible book 12.3x 3.1x 9.3x
EV/EBITDA -10.3x 27.5x 16.9x
EV/EBIT -10.2x -413.9x 22.5x
EV/Revenue 21.6x 3.5x 4.2x
EV/FCF -10.3x 61.3x 16.6x
EV/Operating cash flow -10.3x 35.8x 16.0x
PEG (3Y EPS CAGR) – 1.22 0.64

Growth

14 metrics
MetricCVNEOGLNTH
Revenue growth (1Y) 6.4% -0.3% 2.4%
Revenue CAGR (3Y) – -1.3% 9.0%
Gross profit growth (1Y) -0.5% 1.8% 0.8%
Gross profit CAGR (3Y) – -3.1% 13.9%
Operating income growth (1Y) -30.1% 99.3% -16.3%
Operating income CAGR (3Y) – -29.0% 73.7%
Net income growth (1Y) -29.6% 94.6% 61.0%
Net income CAGR (3Y) – -28.3% 37.4%
EPS growth (1Y) -18.5% 94.6% 59.2%
EPS CAGR (3Y) – -35.7% 38.5%
Operating cash flow growth (1Y) -41.9% -1.9% -10.5%
Operating cash flow CAGR (3Y) – 2.9% 11.1%
Free cash flow growth (1Y) -41.7% 1,631% -5.1%
Free cash flow CAGR (3Y) – 126.1% 119.0%

Profitability

14 metrics
MetricCVNEOGLNTH
Gross margin 49.7% 47.4% 61.3%
EBITDA margin -210.4% 12.5% 24.7%
Operating margin -212.1% -0.8% 18.6%
Pretax margin -209.9% -7.7% 21.9%
Net margin -210.1% -6.3% 17.3%
FCF margin -210.3% 5.6% 25.2%
Operating cash flow margin -209.7% 9.6% 26.2%
Return on equity -148.0% -2.7% 20.2%
Return on assets -114.0% -1.7% 11.1%
Return on invested capital – -0.2% 12.0%
Return on capital employed -151.1% -0.2% 13.9%
Asset turnover 0.5x 0.3x 0.6x
Cash conversion (OCF / net income) 1.0x -1.5x 1.5x
Stock comp / revenue 14.8% 1.3% 4.8%

Financial Health

11 metrics
MetricCVNEOGLNTH
Debt / assets – 23.4% 23.3%
Debt / equity – 0.4x 0.4x
Net debt / EBITDA – 5.4x -0.3x
Debt / FCF – 15.5x 1.5x
Liabilities / assets 19.5% 36.8% 44.8%
Equity / assets 80.5% 63.2% 55.2%
Interest coverage – – 14.7x
Current ratio 5.1x 3.9x 3.2x
Quick ratio 4.0x 2.1x 3.0x
Cash ratio 3.6x 1.2x 2.0x
Altman Z-score 21.14 1.39 5.54

Shareholder Returns

7 metrics
MetricCVNEOGLNTH
Dividend yield – – –
Net buyback yield -4.4% -0.1% 1.3%
Shareholder yield -4.4% -0.1% 1.3%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCVNEOGLNTH
Forward P/E – 35.1xFY2026 17.4xFY2026
EPS, next fiscal year $-0.58FY2026 $0.32FY2026 $5.83FY2026
EPS growth, next FY – 0.0%FY2026 -4.1%FY2026
EPS growth, the year after – +31.3% +7.2%
Revenue, next fiscal year $13.82MFY2026 $847.28MFY2026 $1.58BFY2026
Revenue growth, next FY +2.0%FY2026 -2.7%FY2026 +2.5%FY2026
Revenue growth, the year after +47.0% -1.5% +12.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCVNEOGLNTH
Held by institutions 10.2% 100.0% 100.0%
Institutions holding 50 315 468
Change in shares held, QoQ +27.6% +1.6% +3.4%
Institutions buying 36 150 249
Institutions selling 8 106 143
Buyers to sellers 4.50 1.42 1.74

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CVNEOGLNTH
CV 1.00 0.05 0.06
NEOG 0.05 1.00 0.09
LNTH 0.06 0.09 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CV, NEOG and LNTH?

Lantheus Holdings (LNTH) is the largest by market capitalisation: CapsoVision (CV) $334.51M, Neogen (NEOG) $2.38B, Lantheus Holdings (LNTH) $6.65B.

Which company is growing faster?

CapsoVision (CV) grew revenue fastest over the trailing twelve months: CapsoVision (CV) +6.4%, Neogen (NEOG) -0.3%, Lantheus Holdings (LNTH) +2.4%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (CapsoVision (CV) -210.1%, Neogen (NEOG) -6.3%, Lantheus Holdings (LNTH) 17.3%). On return on invested capital, Lantheus Holdings (LNTH) leads (Neogen (NEOG) -0.2%, Lantheus Holdings (LNTH) 12.0%).

Which stock has performed better?

Over the past year Lantheus Holdings (LNTH) returned the most: CapsoVision (CV) +26.4%, Neogen (NEOG) +70.3%, Lantheus Holdings (LNTH) +91.9%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Neogen (NEOG) -24.3%/yr, Lantheus Holdings (LNTH) +28.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (CapsoVision (CV) 95.6%, Neogen (NEOG) 55.8%, Lantheus Holdings (LNTH) 30.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CV, NEOG and LNTH?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 9. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.